Pharmaceutical Technology

MARCH 29, 2024

Intravacc and Primrose Bio have announced a strategic collaboration aimed at bolstering the conjugate vaccine development and supply.

Vaccination 130

Vaccination Vaccine Development 130

Pharmaceutical Technology

JUNE 6, 2023

Oragenics has secured funding from the Canadian bioresearch consortium CQDM to develop a variant-agnostic protein antigen for use in its Covid-19 intranasal vaccine. In March 2023, Oragenics and Inspirevax entered an exclusive global licence deal to develop the former’s lead intranasal Covid-19 vaccine candidate, NT-CoV2-1.

Vaccination 231

Vaccination Vaccine Development Manufacturing 231

Bio Pharma Dive

MAY 10, 2024

Sanofi will ally with the under-pressure biotech, paying $500 million upfront for rights to co-commercialize Novavax’s COVID shot and develop combination influenza vaccines.

Vaccination 171

Vaccination Vaccine Development 171

Pharmaceutical Technology

JANUARY 25, 2024

Evaxion Biotech has announced plans to develop customised cancer vaccines by targeting a category of AI-discovered tumour antigens.

Vaccination 173

Vaccination Vaccine Development 173

AuroBlog - Aurous Healthcare Clinical Trials blog

MAY 1, 2024

Scientists have developed a vaccine against a notorious drug-resistant superbug, targeting molecules on its surface that are also found on other bacteria and fungi.

Vaccination 187

Vaccination Vaccine Bacteria Drugs 187

Pharmaceutical Technology

MARCH 20, 2023

RVAC Medicines has announced a research collaboration with the University of Pennsylvania (Penn) for the discovery and development of mRNA vaccines. The mRNA vaccine candidates will help reduce the chances of autoimmune responses that might lead to allergic conditions or serious autoimmune diseases.

Vaccination 245

Vaccination Vaccine Development Allergies 245

Pharmaceutical Technology

MAY 15, 2024

CircRNA is still in early days of development, but could be in trials as vaccines, therapeutics and biomarkers in the next few years.

RNA 147

RNA Vaccination Vaccine Trials 147

Pharmaceutical Technology

FEBRUARY 2, 2024

LimmaTech announced the closing of a second round of its Series A financing, securing $3m from Tenmile for vaccine technology development.

Vaccination 130

Vaccination Vaccine Development 130

Pharmaceutical Technology

OCTOBER 14, 2022

German pharmaceutical firm Merck has extended its partnership with Moderna to jointly develop and sell mRNA-4157/V940, an investigational personalised cancer vaccine (PCV). In 2016, the companies entered a strategic partnership to develop novel messenger RNA (mRNA) based PCVs.

Vaccination 289

Vaccination Vaccine Development Immune Response 289

Pharmaceutical Technology

MARCH 25, 2024

Cancer Research UK and the CRIS Cancer Foundation have awarded a £1.7m ($2.1m) grant for developing the lung cancer vaccine LungVax.

Vaccination 246

Vaccination Vaccine Research Development 246

Pharmaceutical Technology

AUGUST 3, 2023

AAHI is developing a novel RNA vaccine that overcomes manufacturing and storage limitations to increase accessibility.

RNA 244

RNA Vaccination Vaccine Development 244

Pharmaceutical Technology

NOVEMBER 25, 2022

XtalPi has entered a strategic partnership with CK Life Sciences for artificial intelligence (AI)-driven tumour vaccine research and development (R&D). Under the collaboration, the companies will utilise their capabilities to co-develop a new AI tumour vaccine R&D platform.

Life Science 246

Life Science Vaccination Vaccine Development 246

Bio Pharma Dive

JANUARY 25, 2021

The drugmaker, one of the largest vaccine developers globally, won't move forward with either of two candidates it's been testing after disappointing data in early trials.

Vaccination 348

Vaccination Vaccine Development Trials 348

Pharmaceutical Technology

AUGUST 1, 2022

GreenLight Biosciences has entered a partnership with the US National Institutes of Health (NIH) for the development of Covid-19 vaccines, which offer broader protection against new variants and with durable effects. They intend to develop vaccines that provide lasting immune responses compared to existing vaccines.

Vaccination 245

Vaccination Vaccine Development RNA 245

Pharmaceutical Technology

MAY 11, 2023

Results published in Nature for a personalised pancreatic cancer vaccine that uses neoantigens from patients’ tumours have lent further support to early positive signals. The vaccine, developed by BioNTech, led to half of the patients with pancreatic cancer in the Phase I trial remaining cancer-free 18 months later.

RNA 345

RNA Vaccination Vaccine Trials 345

Pharmaceutical Technology

SEPTEMBER 21, 2023

The collaboration will use Evaxion’s EDEN platform to bring an AI-designed gonorrhea mRNA vaccine to the market.

Vaccination 246

Vaccination Vaccine Development Marketing 246

Pharmaceutical Technology

MAY 30, 2023

SK Bioscience has received marketing authorisation from the UK’s medicines and healthcare products regulatory agency (MHRA) for its Covid-19 vaccine, SKYCovion. The authorisation allows the distribution of the vaccine in Scotland, Wales and England.

Vaccination 298

Vaccination Vaccine Protein Medicine 298

Bio Pharma Dive

OCTOBER 13, 2023

The awards, to biotechs Gritstone, Codagenix and CastleVax, are part of the program’s plan to develop vaccines with broader or longer-lasting benefits.

Vaccination 276

Vaccination Vaccine Development 276

Pharmaceutical Technology

APRIL 14, 2023

Ghana’s Food and Drug Authority (FDA) has approved R21/Matrix-M malaria vaccine in children aged 5 to 36 months, marking the first regulatory clearance for the University of Oxford-developed vaccine in any country in the world. Children between the ages of five and 36 months are at highest risk of death from malaria.

Vaccination 279

Vaccination Vaccine Manufacturing Containment 279

Pharmaceutical Technology

DECEMBER 18, 2023

The Novo Nordisk Foundation has invested Dkr1.8bn in the initiative to develop vaccines for various airborne infection diseases.

Vaccination 238

Vaccination Vaccine Development 238

Pharmaceutical Technology

NOVEMBER 23, 2023

SK bioscience has signed an agreement with Hilleman Laboratories Singapore for the co-development of a vaccine against the Zaire Ebola virus.

Vaccination 130

Vaccination Vaccine Development 130

Pharmaceutical Technology

SEPTEMBER 19, 2023

BioNTech has entered a strategic collaboration with the CEPI to develop mRNA-based vaccine candidates for monkeypox (Mpox ) prevention.

Vaccination 130

Vaccination Vaccine Development 130

Pharma Times

APRIL 19, 2024

Both will develop cancer vaccine candidates in selected haematological and solid tumour indications

Vaccination 113

Vaccination Vaccine Development 113

Pharmaceutical Technology

MAY 18, 2023

International non-profit research organisation IAVI and Zendal Group’s subsidiary Biofabri have signed an expanded deal to develop MTBVAC, a tuberculosis (TB) vaccine candidate. The organisation and the company initially collaborated in 2021 to advance the vaccine candidate into efficacy trials.

Vaccination 130

Vaccination Vaccine Development Trials 130

Pharmaceutical Technology

MARCH 14, 2023

The National Health Surveillance Agency (ANVISA) in Brazil has granted approval for Takeda ’s dengue virus vaccine candidate, Qdenga (Dengue Tetravalent Vaccine [Live, Attenuated]) (TAK-003). The vaccine has received approval for preventing dengue disease in people aged four years to 60 years.

Vaccination 286

Vaccination Vaccine Clinical Trials Clinical Trials 286

Pharmaceutical Technology

FEBRUARY 3, 2023

Only a few weeks into the new year, the prospect of getting a successful advanced HIV vaccine shrank after the discontinuation of yet another late-stage trial. On January 18, Janssen, a Johnson & Johnson (J&J) subsidiary, stated that its vaccine was not effective in preventing HIV infections.

Vaccination 293

Vaccination Vaccine Antibody Trials 293

Pharmaceutical Technology

APRIL 30, 2024

Repertoire Immune has collaborated with Bristol Myers Squibb to develop tolerising vaccines aimed at treating autoimmune diseases.

Vaccination 130

Vaccination Vaccine Development 130

Pharmaceutical Technology

FEBRUARY 7, 2023

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation for Takeda ’s dengue virus vaccine candidate, Qdenga (Dengue Tetravalent Vaccine [Live, Attenuated]). The vaccine candidate has been approved for active immunisation against the infection in people from four years of age.

Vaccination 264

Vaccination Vaccine Genetics Trials 264

AuroBlog - Aurous Healthcare Clinical Trials blog

JANUARY 22, 2024

The Indian Institute of Science (IISc) is now developing a heat-tolerant vaccine that can offer protection against different strains of SARS-CoV-2 – both current and future variants. The research […]

Vaccination 142

Vaccination Vaccine Development Research 142

Pharmaceutical Technology

JUNE 9, 2023

5+delta) protein vaccine (Sf9 cell). This marks the world’s first Covid-19 vaccine approved for emergency use against XBB descendent lineages of SARS-CoV-2. The vaccine has been developed by WestVac Biopharma along with the West China Medical Center and Sichuan University. recombinant Covid-19 trivalent (XBB.1.5+BA.5+delta)

Vaccination 269

Vaccination Vaccine HR Protein 269

Pharmaceutical Technology

OCTOBER 6, 2022

from the US National Institutes of Health (NIH) unit National Institute of Allergy and Infectious Diseases (NIAID) to develop a prophylactic intranasal vaccine against Neisseria gonorrhoeae (NG). Leveraging its outer membrane vesicles (OMV) platform technology, Intravacc will develop the vaccine.

Vaccination 147

Vaccination Vaccine Development Bacterium 147

BioSpace

MAY 10, 2024

Sanofi will hand Novavax $500 million upfront for its COVID-19 vaccine, which it will co-commercialize and develop into a combination flu-COVID vaccine.

Vaccination 113

Vaccination Vaccine Development 113

Pharmaceutical Technology

SEPTEMBER 7, 2022

Indian company Bharat Biotech International has secured approval from Central Drugs Standard Control Organisation (CDSCO) under Restricted Use in Emergency Situation for its intranasal Covid-19 vaccine, iNCOVACC (BBV154), for usage in people aged 18 years and older. It is formulated to permit intranasal delivery via nasal drops.

Vaccination 263

Vaccination Vaccine Clinical Trials Clinical Trials 263

Pharmaceutical Technology

AUGUST 23, 2023

The US HHS has granted over $1.4bn for Project NextGen to facilitate the development of new vaccines and therapeutics for Covid-19.

Vaccination 130

Vaccination Vaccine Development 130

Bio Pharma Dive

JULY 24, 2023

The shot failed to meet a key goal of Bavarian Nordic’s Phase 3 study, a finding that separates it from marketed vaccines developed by Pfizer and GSK.

Vaccination 246

Vaccination Vaccine Marketing Development 246

Bio Pharma Dive

OCTOBER 12, 2022

The drugmaker’s decision to grab rights to the shot deepens its ties with the COVID-19 vaccine developer and comes weeks before a key data release.

Vaccination 311

Vaccination Vaccine Licensing Licensing 311

Pharmaceutical Technology

NOVEMBER 24, 2022

South African bio-pharmaceutical firm Biovac and the International Vaccine Institute (IVI) in South Korea have signed a licencing and technology transfer agreement for developing and manufacturing an oral cholera vaccine (OCV).

Vaccination 147

Vaccination Vaccine Development Manufacturing 147